Resurgence in Generics
Generics, a cyclical industry, appears to be on the upswing, as recent deals suggest. Alpharma is buying the Cox Pharmaceutical business of Hoechst to expand its generics presence in Europe, while Merck KGAA is buying a 42% stake in Pharmaceutical Resources, a moribund American company, to gain a sales and administrative infrastructure in the US for its growing generics business
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.